Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Earnings for Ginkgo Bioworks Holdings, Inc. (DNA)
Earnings in 2023 (TTM): $-892,940,000
According to Ginkgo Bioworks Holdings, Inc.'s latest financial reports the company's current earnings (TTM) are $-892,940,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ginkgo Bioworks Holdings, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-892,940,000 | $-892,869,000 |
| 2022 | $-2,121,399,000 | $-2,104,929,000 |
| 2021 | $-1,838,122,000 | $-1,830,047,000 |
| 2020 | $-124,834,000 | $-126,609,000 |
| 2019 | $-119,835,000 | $-119,327,000 |
| 2001 | $ | $ |